Skip to main content
. 2023 Sep 5;12(2):2249121. doi: 10.1080/22221751.2023.2249121

Table 1.

Baseline characteristics of study participants one month after breakthrough infection.

  All The young-adult Cohort The Elder Cohort
All the elders Fully vaccinated Not–fully Vacccinated
N 134 53 81 40 41
Gender, male (%) 67 (50) 21 (39.6) 46 (56.8) 21 (52.5) 25 (61)
Age, median (IQR) 69 (39–81) 33 (27–42) 80 (69–88) 75.5 (69–81.25) 83 (69–91)
Comorbidities, N (%) 87 (64.9) 12 (22.6) 75 (92.6) 36 (90) 39 (95.1)
 Smoke, N (%) 16 (11.9) 3 (5.7) 13 (16) 10 (25) 3 (7.3)
 Alcohol Abuse, N (%) 12 (9) 3 (5.7) 9 (11.1) 8 (20) 1 (2.4)
 Obesity BMI > 28, N (%) 11 (8.2) 6 (11.3) 5 (6.2) 3 (7.5) 2 (4.9)
 hypertension, N (%) 45 (33.6) 5 (9.4) 40 (49.4) 24 (60) 16 (39)
 Heart Conditions, N (%) 36 (26.9) 0 (0) 36 (44.4) 17 (42.5) 19 (46.3)
 Cardiovascular Disease, N (%) 23 (17.2) 0 (0) 23 (28.4) 10 (25) 13 (31.7)
 Chronic Lung Disease, N (%) 6 (4.5) 0 (0) 6 (7.4) 2 (5) 4 (9.8)
Vaccination ≥ 2doses, N (%) 91 (67.9) 51 (96.2) 40 (49.4) 40 (100) 0 (0)
 Heterogenous Booster 21 (39.6)
 Homogenous Booster 19 (35.8)
Median (IQR) Days From Last Vaccination to Breakthrough Infection 384.5(126.75–490) 481(380–500) 172(66–243) 182(79–228.5) 124.5(31.5–267.75)
WT, GMT [95%CI] 489 (383–623) 1182 (950–1470) 274 (199–378) 745 (560–991) 104 (71–151)
BA.2, GMT [95%CI] 726 (601–877) 717 (561–915) 733 (558–962) 1071 (770–1490) 506 (335–765)
BA.5, GMT [95%CI] 585 (478–716) 716 (569–901) 513 (381–692) 744 (530–1046) 357 (222–574)
BA.7, GMT [95%CI] 503 (427–593) 570 (469–692) 464 (364–592) 605 (467–782) 358 (239–537)
BQ.1.1, GMT [95%CI] 236 (193–289) 353 (267–467) 181 (138–238) 233 (172–314) 142 (91–223)
CH.1.1, GMT [95%CI] 258 (209–318) 196 (154–250) 308 (227–420) 303 (208–441) 314 (190–519)
XBB.1.5, GMT [95%CI] 157 (132–187) 222 (178–277) 125 (99–159) 149 (113–196) 106 (72–156)

Abbreviations: IQR: Interquartile Rangel; WT wild type; GMT: Geometric Mean Titre; CI: Confidence Interval.